updated ballieu report - target range 25-55c, page-45

Npone..welcome .
Your post raises some good questions as to the hsv2 vaccines ability to deal with the very clever herprs virus.

I think prof frazer has already spoken about the importance of his vaccinne being able to deal with the virus when it comes out of latency.

Regarding the difference in the ability of the virus to evade detection in humans as opposed to mice, this would be based on mutations it could only do in the human host. However from my quick research on that, once it mutates it basically dies or looses the ability to regenerate.

Bill Hanaford is a critic of Frazer but even he covers that issue nicely:

"HSV-2 is a wondrous feat of co-evolution between virus and host. This is its strength in terms of why it is so damned hard to control / get rid of with creams, antiviral drugs, etc. However, in the case of vaccines, this is HSV-2's Achilles’ heel……if HSV-2 underwent random mutations in an attempt to escape an effective HSV-2 vaccine (as you propose), it would simultaneously lose its ability to complete an incredibly complex life cycle."

Hope that helps.
Fox